###### Strengths and limitations of this study

-   Comprehensive and focused search strategy on prognostic models built around survival outcomes rather than shorter-term surrogates.

-   Contemporary clinical review of model accuracy and usability, to inform clinical practice.

-   Thorough bias assessments of individual studies, utilising the newly developed PROBAST tool.

-   Unable to assess bias across studies, publication bias and selective reporting.

Introduction {#s1}
============

Prostate cancer (PCa) is the most common male cancer and its incidence is increasing, with 1.3 million estimated new cases globally in 2018.[@R1] The vast majority of new presentations in the UK (\>80%) are with localised or locally advanced disease representing a significant healthcare and economic burden.[@R3] Treatment decisions, in this growing group of men, are notoriously complex with the risk of progression and psychological impact of a cancer diagnosis balanced against significant potential morbidity associated with treatment. These latter problems can be very significant with rates of erectile dysfunction as high as 79% and 66% 3 years after prostatectomy and radiotherapy, respectively, and incontinence rates of 20% and 3%, respectively[@R4]. As a result of this, the uptake of conservative management is increasing with rising confidence in using active surveillance.[@R5] The predominant decision dilemma is therefore at the point of diagnosis when men are considering treatment options and indeed whether treatment is needed, particularly given the fact that many men may have indolent disease and are more likely to die of non prostate cancer related causes. This point is highlighted in the work of Lloyd *et al* who showed that the lifetime incidence of being diagnosed with the disease is 13.4% but the risk of dying from the disease is only 4.3%.[@R7]

Most national guidelines currently risk-stratify men according to modified versions of the three-stratum D'Amico classification system, first proposed in 1998[@R8]. This used biochemical recurrence as the primary outcome from a cohort of men all managed by radical treatment. However, biochemical recurrence is known to be a poor surrogate for survival and many men will no longer undergo radical treatment.[@R5] The value of this system is therefore questionable, especially given its use has moved from predicting radical therapy outcomes to counselling men at diagnosis about whether to have surveillance or treatment. Alternative risk models have been proposed to delineate smaller groups using standard variables (prostate-specific antigen (PSA), Gleason score, T-stage) or which integrate additional parameters, such as biopsy characteristics.[@R10] However, many are built around single-centre data, using PSA-screened and heavily radically-treated populations, making them less applicable to the fundamental decision dilemma of whether treatment is needed in the first place.

Prognostic models, according to the American Joint Committee on Cancer (AJCC), should use survival itself as an endpoint, which is less equivocal and more robust.[@R13] Using survival is especially important in prostate cancer given the slow natural history of the disease. In other tumour-types, high quality prognostic models using long-term survival are already integrated into routine practice and endorsed by the AJCC.[@R14] However, no prognostic model for PCa has yet been endorsed, nor to our knowledge, is any such model widely-used in routine clinical practice. Models integrating the impact of radical treatment compared with conservative management would be particularly powerful.

Our objective in this study was therefore to perform a rigorous systematic search of the literature to identify available prognostic models built specifically around long-term patient survival, available for use at the point of a new diagnosis of primary non-metastatic PCa. Our aims were to establish (i) what models were available (ii) their accuracy in terms of discrimination and calibration and (iii) their generalisability, external validation and clinical utility.

Methods {#s2}
=======

The study protocol followed the recommendations of Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.[@R15] The review aim, search strategy and study inclusion and exclusion criteria were framed using the CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS).[@R16] The search strategy was informed by previous similar studies, including publications which tested and recommended search terms for risk-prediction models.[@R17] The full systematic review protocol was pre-specified and registered through PROSPERO, reference CRD42018086394 (<https://www.crd.york.ac.uk/prospero/>) and is available in the online [supplementary files](#SP2){ref-type="supplementary-material"}.

10.1136/bmjopen-2019-029149.supp2

In summary, this was a review of studies reporting multivariable long-term survival models for use at the point of diagnosis for men newly diagnosed with non-metastatic PCa. Long-term survival, was defined as ≥5 years following diagnosis. We focused on publications subsequent to January 2000 to increase relevance to modern practice. For inclusion, studies needed to include men undergoing more than one treatment type and models should be multivariable. Models for cancer-specific or all-cause survival outcomes were potentially eligible, and any eventual model types were allowable. Both model development and model validation studies were eligible. Single-parameter or single-treatment studies were excluded. Comprehensive study inclusion and exclusion criteria are shown in [box 2](#B2){ref-type="boxed-text"}.Box 1Eligibility criteria for study inclusion and exclusion**Study inclusion criteria**All of the following inclusion criteria must be met:Studies reporting models based on men with non-metastatic prostate cancer.Studies evaluating 'long-term' (≥5 years) cancer-specific or overall survival outcomes.Studies reporting models in screened or non-screened populations.Studies including men undergoing more than one treatment option.Models available for use at the point of diagnosis -- that is, pre-treatment.The model includes more than one parameter, that is, multivariable.**Study exclusion criteria**Any of the following is a reason to exclude a study:Any article that is not an original study (eg, reviews, commentary, editorials, corrigendums, letters).Conference proceeding or abstract from poster/oral communication only.Study where data cannot be derived to contribute to a primary or secondary outcome of this systematic review.Studies pertaining only to men with advanced/metastatic disease.Studies pertaining exclusively to men **after** an active treatment option for example, after radical prostatectomy.Studies of single biomarkers or single parameters only.Studies including men exclusively undergoing a single treatment type.

Information sources {#s2a}
-------------------

Studies were identified by searching MEDLINE, Embase and Cochrane Library from 1 January 2000 to 28 February 2018. Detailed search strategies for each database are available in the online [supplementary data](#SP1){ref-type="supplementary-material"}. Highly relevant but excluded articles were recorded, collated and the references analysed for additional studies.
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Data management {#s2b}
---------------

Search results were exported into Covidence software, an online screening platform endorsed by Cochrane (covidence.org). Title and abstract screening and full-text screening were sequentially performed by a team of three reviewers. Prior to screening, a pilot screening process was conducted for calibration of screening between reviewers. Reviewers were not blinded to study authors, institution, publication journal or year of publication.

Data items {#s2c}
----------

The full list of data items extracted from each included study is recorded in the protocol. These were informed by the CHARMS checklist[@R16] and included: (1) Study design, (2) Characteristics of study participants, (3) Outcomes, (4) Candidate predictors, (5) Sample size, (6) Missing data, (7) Statistical methods, (8) Model performance and evaluation and (9) Usability. Model performance, assessed by discrimination was the principal summary measure.

Bias assessment {#s2d}
---------------

To assess the validity of eligible studies, individual studies were assessed for bias using the new Prediction model Risk Of Bias ASsessment Tool (PROBAST).[@R19] The PROBAST tool assesses both risk of bias and applicability of both model development studies and validation studies.[@R20]

Patient and public involvement {#s2e}
------------------------------

There was no formalised patient and public involvement in the design or conduct of this review. Preliminary results were presented to a departmental patient and public involvement group, and their comments used to inform the write-up of the review.

Results {#s3}
=======

Study selection {#s3a}
---------------

The search of Cochrane, MEDLINE and Embase yielded 6581 studies after deduplication. Sixteen additional studies were identified by reviewing the references of excluded but relevant studies. A total of 12 studies were eligible for inclusion in the final review.[@R21] Two of these had not been summarised in previous reviews.[@R26] The PRISMA flow diagram is shown in [figure 1](#F1){ref-type="fig"}, including the reasons for exclusion at full-text screening. Only one reason for exclusion was assigned to each study, when multiple reasons may have been present. Nine of the final 12 included studies were model development studies, three were model validation studies. Two of these external validations were of models already included as model development studies.[@R30] One study related to an external validation of the Cancer of the Prostate Risk Assessment (CAPRA) score against mortality.[@R32] The original CAPRA model development study however did not meet the eligibility criteria as it was developed against recurrence rather than long-term survival.[@R11]

![PRISMA flow diagram depicting the flow of information through the different phases of the review. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.](bmjopen-2019-029149f01){#F1}

Study characteristics {#s3b}
---------------------

Characteristics of the included studies' participants and settings are summarised in [table 1](#T1){ref-type="table"}. The model development studies used data from over 231 888 men. However, two studies used analytical cohorts from the same registry (Surveillance, Epidemiology and End Results (SEER)).[@R23] Two studies used data from single US centres, two used data from groups of four hospitals, and five were from regional or national multicentre registries. Eligibility criteria of patients into studies varied significantly, with some models using very specific or selected sub-cohorts only. For example Nguyen *et al* included only consenting men, undergoing radiotherapy (RT) or radical prostatectomy (RP), with at least one intermediate or high-risk feature but ≤T3b disease.[@R22] The treatment cohorts included, and whether treatment effect was a parameter in the final model was highly variable. Only six of the nine models included any men who had been managed conservatively (including 'watchful waiting' or 'conservative management'); none of the models described or defined a specific 'active surveillance' cohort.[@R21] Only three of the nine models included treatment as a predictor variable - none of which were externally validated.[@R24] Median follow-up was relatively short within all model development cohorts, with the longest reported follow-up being 7.6 years[@R26].

###### 

Study characteristics of model development studies -- participants and setting

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                              Source of data                       Country             Years of diagnosis   Eligibility summary                                                                                                                                            Overall (n)   Number of PCa deaths   Number of overall deaths   Treatment cohorts included          Median follow-up
  ---------------------------------- ------------------------------------ ------------------- -------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------- ---------------------- -------------------------- ----------------------------------- ------------------
  Margel *et al* 2014[@R21]          Registry (Ontario Cancer Registry)   Canada              1994--2008           Aged 66+, with diabetes prior to PCa diagnosis and pathology reports available                                                                                 4001          321                    1395                       Surgery, RT, WW, ADT                4.7 years

  Nguyen *et al* 2009[@R22]          Hospital data (four centres)         USA                 1965--2002           Consenting men who had RP or RT or RT+ADT for up to T3b PCa at four centres with at least one int/high risk factor (PSA\>10, GL7+, t2b+, PSAV\>2.0 ng/mL/yr)   1063          178                    NR                         Surgery, RT, RT+ADT                 5.6 years

  Feuer *et al* 2012[@R23]           Registry (SEER)                      USA                 1995--2005           PCa, aged 40--96, with complete information and cause of death (and linked medicare data if aged 66+)                                                          203 546       NR                     NR                         All                                 NR

  Kutikov *et al* 2012[@R24]         Registry (CaPSURE)                   USA                 NR                   Localised PCa, undergoing RT or RP                                                                                                                             6091          167                    983                        Surgery, RT                         4.4 years

  Cowen *et al* 2006[@R25]           Hospital data (single centre)        USA                 1987--1989           Clinically localised PCa (\<cT3) with known initial treatment strategy                                                                                         506           NR                     321                        Surgery, RT, other (inc CM, cryo)   NR

  Kerkmeijer *et al* 2016[@R26]      Hospital data (four centres)         Belgium & Holland   1989--2008           Treated PCa patients only                                                                                                                                      3383          149                    628                        Surgery, RT, brachytherapy          7.6 years

  Gnanapragasam *et al* 2016[@R27]   Registry (NCRS Eastern)              UK                  2000--2010           All clinically localised PCa with intact data for included variables                                                                                           10 139        462                    1557                       Surgery, RT, CM, brachytherapy      6.9 years

  Tewari *et al* 2004[@R28]          Hospital data (single centre)        USA                 1990--1997           Men under 75 with localised PCa, negative bone scan and intact data including zip code                                                                         3159          NR                     NR                         Surgery, RT, CM                     6.2 years

  Howlader *et al* 2014[@R29]        Registry (SEER)                      USA                 1992--2009           All PCa patients\                                                                                                                                              NR            NR                     NR                         All                                 NR
                                                                                                                   (the model including comorbidity includes men aged 66+only)                                                                                                                                                                                                        
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ADT, androgen deprivation therapy; CaPSURE, UCSF Cancer of the Prostate Strategic Urologic Research Endeavor; CM, conservative management; inc, including; int, intermediate; NR, not recorded; PCa, prostate cancer; PSA, prostate-specific antigen; PSAV, prostate-specific antigen velocity; RP, radical prostatectomy; RT, radiotherapy; SEER, Surveillance, Epidemiology and End Results; WW, watchful waiting.

Results of individual studies {#s3c}
-----------------------------

The final results of individual studies are summarised in [table 2](#T2){ref-type="table"}. The primary outcome was cancer-specific mortality only in one study,[@R27] and was overall-survival only in another study.[@R25] The remainder reported measures of both. The study designs, model-types and performance metrics varied markedly. We therefore focused on describing the studies, results, applicability and availability. Significant heterogeneity in the question being asked and statistical methods of validation between studies meant that attempts to meta-analyse data would not be appropriate. Modelling techniques varied, with the majority of studies using a proportional hazards model (Cox or Fine and Grey) although none reported assessing whether the proportional hazards assumption was valid. Included studies did not report any flexible parametric approaches to deal with continuous variables, and the majority used group categorisations of these variables. Reporting of model accuracy was inconsistent. Considering area under the curve and c-indices synonymously, six of the nine studies reported some measure of discrimination with values ranging from 0.63 to 0.90 for PCa survival outcomes, although this higher figure was derived within a small elderly sub-cohort[@R23] and 0.58 to 0.73 for overall outcomes.[@R23] Only four of the nine studies reported assessing calibration in some capacity.[@R23] Relative performance within particular sub-populations were not generally reported.

###### 

Study characteristics of model development studies: analysis and model output

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                              Outcome(s) or endpoint(s)          Time frame of predictions         Model type                   Statistical methods   Included predictors                                                                                                                                                Missing data handling    Number of groups          Internal validation method        Discrimination results (c-index or AUC)                                                         Calibration results   Model availability
  ---------------------------------- ---------------------------------- --------------------------------- ---------------------------- --------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------ ------------------------- --------------------------------- ----------------------------------------------------------------------------------------------- --------------------- ------------------------------
  Margel *et al* 2014[@R21]          PCSM and ACM                       5 year                            N/A                          Nested Cox model      Two models: 1=age, Johns Hopkins comorbidity group, year of cohort entry, socioeconomic status and housing status. 2=as above + Gleason grade and cancer volume.   Complete case analysis   N/A                       Bootstrapping                     Admin data only model ACM c-index 0.70 (95% CI 0.69 to 0.71) PCSM 0.76 (95% CI 0.74 to 0.78)\   NR                    No
                                                                                                                                                                                                                                                                                                                                                                                                                     Extended model ACM 0.74 (95% CI 0.73 to 0.75)\                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                     PCSM: 0.85 (95% CI 0.83 to 0.87)                                                                                      

  Nguyen *et al* 2009[@R22]          PCSM and ACM                       5 year                            Group-based stratification   Fine & Grey           PSA, PSAV, stage, Gleason                                                                                                                                          NR                       four groups               KM curves only                    NR                                                                                              NR                    Yes - paper

  Feuer *et al* 2012[@R23]           PCSM, OCM and LE                   3--5 and 10 year                  Nomogram                     Cox model             Preclinical model: stage, Gleason, age, race, marital status, (comorbidity if 66+)                                                                                 Complete case analysis   'Individualised'          Time dependent AUC                10 year AUCs: Pretreatment model: \<66 years, PCSM 0.82, OCM 0.69, 66+yrs PCSM 0.87, OCM 0.61   Plots                 No

  Kutikov *et al* 2012[@R24]         PCSM and NPCM                      10 year                           Nomogram                     Fine & Grey           Age, race, comorbidity, primary treatment (RT vs RP), receipt of ADT and modified CAPRA score                                                                      Imputed mean values      Nomogram                  NR                                NR                                                                                              NR                    Yes - paper

  Cowen *et al* 2006[@R25]           Overall survival                   5, 10 and 15 year and median LE   Nomogram                     Cox model             Age, Charlson, performance status, angina, BMI, smoking, marital status, PSA, Gleason, treatment                                                                   Imputation               260 points                Within complete case sub-cohort   c-index 0.73                                                                                    Plots                 Yes - paper

  Kerkmeijer *et al* 2016[@R26]      DSS and OS                         10 year DSS                       Nomogram                     Cox model             T-stage, grade(on 1--3 scale) PSA, age                                                                                                                             Single imputation        16 points - five groups   Bootstrapping                     c-index 0.78 (95% CI 0.74 to 0.82) DSS, 0.68 (95% CI 0.65 to 0.70) OS                           Plots                 Yes - paper

  Gnanapragasam *et al* 2016[@R27]   PCSM                               N/A                               Group-based stratification   Cox model             PSA, grade group, T-stage integers                                                                                                                                 Complete case analysis   five groups               Random validation cohort          c-index 0.75 (95% CI 0.72 to 0.77) for PCSM                                                     Plots                 Yes - paper and online model

  Tewari *et al* 2004[@R28]          PCSM and ACM                       10 year                           Look up tables               Cox model             Age, grade (three groups), PSA, treatment, comorbidity, race                                                                                                       Complete case analysis   n/a                       Unclear                           0.63 PCSM, 0.69 OS                                                                              NR                    Yes - paper

  Howlader *et al* 2014[@R29]        OS, PCa death, other cause death   5 year                            Look up tables               Unclear               Age, stage (localised/regional/distant), comorbidity                                                                                                               NR                       n/a                       NR                                NR                                                                                              NR                    Yes - paper
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

 ACM, all cause mortality; AUC, area under the curve; BMI, body mass index; CAPRA, Cancer of the Prostate Risk Assessment; DSS, disease specific survival; KM, Kaplan-Meier; LE, life expectancy; N/A, not available; NPCM, non prostate cancer mortality; NR, not recorded; OCM, other cause mortality; OS, overall survival; PCa, prostate cancer; PCSM, prostate cancer specific mortality; PSA, prostate-specific antigen; PSAV, prostate-specific antigen velocity.

Validation {#s3d}
----------

Seven of the nine model development studies reported internal validation. Two reported using bootstrapping, and one used a separate 40% random sample of the original dataset for internal validation.[@R21] An additional three external validation papers were included ([table 3](#T3){ref-type="table"}). Of note, each of these included the author of the original model within their author list, suggesting these are not completely independent validations. These three models each used large numbers of subjects over comparable timeframes to their model development study. Discrimination of the Cambridge Prognostic Groups, SEER Cancer Survival Calculator and CAPRA scores were comparable for prostate cancer specific mortality (PCSM) at 0.81, 0.81 and 0.80, respectively, over 5 years[@R30] ([table 4](#T4){ref-type="table"}). Discrimination was poorer for overall mortality at 0.71 in the latter study. These external validation papers performed quite well on individual bias assessment ([table 5](#T5){ref-type="table"}). In the CAPRA validation paper estimates were reported to be 'adjusted' for age and treatment type, such that it is unclear whether the reported accuracy reflects that of the usable model.[@R32]

###### 

Study characteristics of external validation studies: participants and setting

  Study                              Source of data                                                Country              Years of diagnosis   Eligibility summary                                                              Overall (n)                      Number of PCa deaths            Number of overall deaths          Treatment cohorts included   Median follow-up
  ---------------------------------- ------------------------------------------------------------- -------------------- -------------------- -------------------------------------------------------------------------------- -------------------------------- ------------------------------- --------------------------------- ---------------------------- -------------------------------------
  Gnanapragasam *et al* 2018[@R31]   Registry (PCBaSe) & hospital data (single Singapore centre)   Sweden & Singapore   2000--2010           All non-metastatic PCa with intact data on included variables                    Sweden: 72 337 Singapore: 2550   7162 (Sweden) 142 (Singapore)   23 083 (Sweden) 408 (Singapore)   All                          7 years Sweden, 4.1 years Singapore
  Feuer *et al* 2014[@R30]           Hospital data (single US centre)                              USA                  2001--2008           Aged 40--94, intact staging details & 1 year of information prior to diagnosis   1102                             NR                              NR                                All                          NR
  Cooperberg *et al* 2009[@R32]      Registry (CaPSURE)                                            USA                  \<July 2007          Localised PCa (\<T3b), with \>6/12 follow-up, treatment known and intact data    10 627                           NR                              1833                              All                          5.9 years

NR, not recorded; PCa, prostate cancer; PCBaSe, Prostate Cancer dataBase of Sweden.

###### 

Study characteristics of external validation studies: analysis and model output

  Study                              Outcome(s) or endpoint(s)   Time frame of predictions   Model type          Statistical methods              Included predictors                                                                                   Missing data handling                                   Number of groups    Discrimination results                                              Calibration results   Model availability
  ---------------------------------- --------------------------- --------------------------- ------------------- -------------------------------- ----------------------------------------------------------------------------------------------------- ------------------------------------------------------- ------------------- ------------------------------------------------------------------- --------------------- -------------------------
  Gnanapragasam *et al* 2018[@R31]   PCSM                        10 year mortalities         Five groups         N/A                              PSA, grade group, T-stage integers                                                                    Complete case analysis                                  Five groups         c-index 0.81 for PCSM in Sweden, 0.79 in Singapore                  NR                    Yes - papers and online
  Feuer *et al* 2014[@R30]           DSS and OS                  1, 3, 5, 7, 10 years        Nomogram - online   As per development study[@R30]   Grade (three categories), stage, marital status, age, race, year of diagnosis and comorbidity score   Complete cases + weighted averages for marital status   'Individualised\'   AUCs (5 year:) 0.81 PCSM, 0.81 OCM, (10 year:) 0.77 PCSM 0.76 OCM   Curves                No
  Cooperberg *et al* 2009[@R32]      PCSM and ACM                Five and 10 year survival   Score               Cox prop hazards                 CAPRA (& primary treatment, age and comorbidity in multivariable analysis)                            Mixed                                                   10 groups           PCSM 0.80 OCM 0.71                                                  NR                    Yes - papers and online

ACM, all cause mortality; AUC, area under the curve; CAPRA, Cancer of the Prostate Risk Assessment; DSS, disease specific survival; N/A, not available; NR, not recorded; OCM, other cause mortality; OS, overall survival; PCSM, prostate cancer specific mortality; PSA, prostate-specific antigen.

###### 

Individual study bias and applicability summary using the PROBAST tool

  Study                                Risk of bias   Concern regarding applicability   Overall                                               
  ------------------------------------ -------------- --------------------------------- --------- --------- --------- ------ ------ --------- ---------
  Model development studies                                                                                                                   
   Margel *et al* 2014[@R21]           high           high                              low       high      high      high   low    high      high
   Nguyen *et al* 2009[@R22]           high           high                              high      high      high      low    high   high      high
   Feuer *et al* 2012[@R23]            high           unclear                           low       high      high      low    low    high      high
   Kutikov *et al* 2012[@R24]          unclear        low                               low       high      low       high   low    high      high
   Cowen *et al* 2006[@R25]            high           unclear                           unclear   high      unclear   low    low    high      unclear
   Kerkmeijer *et al* 2016[@R26]       low            low                               high      unclear   low       low    low    high      low
   Gnanapragasam *et al 2016* [@R27]   high           low                               low       high      low       low    low    high      low
   Tewari *et al* 2004[@R28]           high           low                               low       high      unclear   low    low    high      unclear
   Howlader *et al* 2014[@R29]         unclear        high                              low       high      high      low    low    high      high
  External validation studies                                                                                                                 
   Gnanapragasam *et al* 2018[@R31]    high           low                               low       high      low       low    low    high      low
   Feuer *et al* 2014[@R30]            unclear        low                               unclear   unclear   low       low    low    unclear   low
   Cooperberg *et al* 2009[@R32]       low            high                              low       high      low       low    low    high      high

PROBAST, Prediction model Risk Of Bias ASsessment Tool.

Risk of bias {#s3e}
------------

Risk of bias within studies is summarised in both [table 5](#T5){ref-type="table"} and [figure 2](#F2){ref-type="fig"}. Frequent concerns were observed with respect to participant selection and inclusion, particularly with respect to reporting or allowing for missing data. The outcome of death was well-defined and unambiguous in the majority of studies. Every included study had at least one parameter for which there was high concern of bias -- leading to a high overall judgement of bias in the PROBAST tool. Concerns about applicability to the review question were present in more than half of the studies.

![Bias assessment summary (across both the model development and model validation studies).](bmjopen-2019-029149f02){#F2}

Usability {#s3f}
---------

All of the included studies reported models that were nomograms, look-up tables or grouping stratifications. Seven of the nine studies were clinically usable through the publication itself. One was also available in a dedicated website.[@R31] The SEER Cancer Survival Calculator was never launched online, and the publication itself does not provide sufficient detail to use the model.[@R23] The model by Margel *et al* was available but not usable as it included year of entry as a predictor variable, making the model usable only on retrospective series rather than in future individual cases. Indeed, this model was developed to answer the question of whether pathological information adds to a prognostic model, rather than being intended for use at diagnosis.[@R21]

Discussion {#s4}
==========

Principal findings {#s4a}
------------------

Treatment decisions at the point of diagnosis of non-metastatic PCa should be informed by the likely prognosis of the disease. Despite finding a number of published prognostic models, there remains a lack of well-validated, unbiased, generalisable models for use at diagnosis. In particular, there was a lack of external validation and dearth of models that compare outcomes between conservative management and radical treatment.

Prior evidence {#s4b}
--------------

A number of previous reviews have assessed 'prediction' or 'risk' models in their broadest sense.[@R33] Shariat *et al* have previously published a thorough catalogue of available predictive models in PCa -- predicting everything from detecting PCa in the initial biopsy setting to survival. Other reviews have focused exclusively on outcomes following radical prostatectomy or radiotherapy.[@R36] Lughezzani *et al* in 2010 for example summarised models predicting Gleason score upgrading, pathological stage, life expectancy, perioperative mortality, postoperative biochemical recurrence or functional outcomes in addition to PCSM after prostatectomy.[@R36] The paucity of models using mortality as an outcome was particularly noted and the study concluded that no tools were capable of quantifying the benefit of RP relative to other treatment modalities.[@R36] In 2009, a separate review by Shariat *et al* summarised available models into eight groups. One of these groups was of models predicting survival. This group included only four models, all of which related to advanced or metastatic disease requiring hormonal therapy, or androgen-insensitive disease.[@R33] Green *et al* explored more historical literature from 1966 until 2012.[@R35] They included four studies which looked at life expectancy in men with localised PCa, two of which were included in our study.[@R25] The other two were models from Albertsen *et al* in 1996 which was prior to our study dates, and from Walz *et al* in 2007 which focused exclusively on non-cancer mortality and therefore did not meet our eligibility criteria.[@R38] A recent review into decision-making tools again took an overview of tools available for use at different points in the patient pathway.[@R40] Here, the only mentioned models that predicted survival were all post-prostatectomy models.[@R40] In 2015 Kent and Vickers reported on 'gross deficiencies' in current tools for prediction of non-PCa death and concluded that they were unable to identify a suitable life expectancy tool.[@R41] These previous reviews all suggest there is a lack of focus on and availability of good quality survival models.

Interpretation of findings {#s4c}
--------------------------

Although a number of previous reviews have been published, ours represents the most systematic and contemporary work focused towards the decision dilemma that patients and clinicians face, as it includes only models that are available at the pretreatment stage and that are not treatment-specific. This review demonstrates that only a small number of models for this setting have been published using long-term survival as an endpoint, and only three have been externally validated. However, the number of events reported in these three validation studies were well in excess of the 100 suggested as the minimum number needed for adequate validation.[@R42] Within the external validations, model discrimination of up to 0.81 was reported for disease related mortality.[@R30] The included studies highlight the potential for using large datasets to develop prognostic models. These have the advantage of providing data from 'real-world' settings, outside of the clinical trial context or data exclusively from specialised centres. Our included studies commonly used elements of good study design that would be in keeping with the AJCC acceptance criteria for risk models.[@R13] For example, criteria that were seen in all studies, were that the prognostic time-zero was well-defined, and that model developments have been published in well regarded peer-reviewed journals. However, other criteria were lacking such as reporting measures of discrimination, assessing calibration and thorough reporting of missing data in validation work.

The most robust tools we found are the three that have been externally validated -- namely the Cambridge Prognostic Groups, The SEER Cancer Survival Calculator and the UCSF CAPRA score. Of note, the Cambridge Prognostic Group stratification criteria has not previously been summarised in prior reviews, as both its development and validation have been published in the last few years.[@R27] However, the SEER calculator has never been released for public use. Each of the other two models have significant shortcomings by disregarding treatment effect, focusing only on disease-specific mortality and ignoring comorbidity such that their value at the point of diagnosis is diminished. Importantly, each of the three external validation studies also had potential flaws in their design, using predominantly complete-case analyses and non-independent authors.[@R30]

Many of the included studies used historical cohorts. This is a necessity when using long-term survival as an outcome, but, raises issues of generalisability to men diagnosed in the contemporary setting. The uptake of prebiopsy multiparametric MRI and targeted biopsies, may for instance impact on the type of PCa detected and affect generalisability of previous models to current practice.[@R43] Another issue was of small cohorts and low numbers of events in some cases, often as a result of relatively short follow-up. The value of 5 year outcomes themselves is questionable given randomised control trial data on survival in non-metastatic PCa would suggest cancer-survival over this timeframe is incredibly high.[@R44] An important feature of any prognostic model should be its usability and applicability to a man diagnosed today. However, with unquantified missing data this applicability becomes less clear. Dealing with PCSM in isolation may also be problematic, not least because of the importance of competing risks of death in a disease that affects older men.[@R45] In this review we see that all but two included models were derived from North American data, such that generalisability to European or UK men could be questioned, with differing approaches to PSA-testing and different healthcare contexts. This is particularly relevant with regards to screening, whereby historical American cohorts are likely to have been detected through PSA screening, such that issues of lead time bias and detection of cancers that would not be considered clinically-significant may affect model generalisability to modern practice.

Access for clinicians and patients to know about and use models should be easy with modern web-based software. However, we found models were often only available in paper nomograms published with the article. Rather than online resources increasing the availability of models, there is the suggestion of the opposite occurring, with sites such as [www.nomogram.org](http://www.nomogram.org) and [www.clinicriskcalculators.org](http://www.clinicriskcalculators.org) which were previously cited in reviews no longer being available online.[@R36] Indeed, the SEER Cancer Survival Calculator, one of the most promising models we explored, which was also externally validated, was never made available online or for clinical use.[@R23] The UCSF CAPRA score ([www.urology.ucsf.edu](http://www.urology.ucsf.edu)) and Cambridge Prognostic Groups ([www.cambridgeprognosticgroup.com](http://www.cambridgeprognosticgroup.com)) on the other hand are freely available online. Online publication does not in itself difficulty in accessing models, or a reluctance to fully share coefficients may partly explain the lack of external validations by researchers outside of the original models' authorship group. Another hurdle to acceptance will be the 'face validity' of a model. For example, in any PCa prognostic model clinicians would likely expect grade, PSA and stage to be incorporated as a minimum set of variables; each of which has been shown to be independently prognostic.[@R46] However, two of the models based on the largest dataset failed to include PSA which is inadequately recorded in the SEER database.[@R23] A number of the other models used 3-strata grade classifications, rather than the full Gleason grade system, or the contemporary grade group system, which would again seem inadequate for a modern PCa model.[@R49]

A key step in the development of any prognostic model, following validation, should be a clinical impact study to quantify whether the model's use improves decision-making and patient outcomes within a comparative design.[@R50] Reviewing clinical impact studies was beyond the scope of this formalised review, but no such studies were found on simple literature review. These studies not only assess whether use of the model is an improvement on standard care, but also enable the study of factors that may affect implementation into care, such as the acceptability and ease of use to clinicians or patients, which can be difficult to assess in a review such as this.[@R50] Impact studies can also help to bridge the gap between clinical validity and clinical utility, as utility of a model is not proportional to its prognostic capabilities. This has recently been explored further in a review on the UCSF CAPRA score, which confirmed its prognostic capacities, but was unable to demonstrate clinical usefulness -- particularly when deliberating between different treatment strategies.[@R51]

Strengths and limitations at review level {#s4d}
-----------------------------------------

While this review has particular strengths in its broad coverage of the literature and search strategy, we recognise potential limitations. Although we have assessed bias within individual studies we recognise that risk of bias will also exist across studies, driven particularly by publication bias and selective reporting within studies which we were unable to assess. Other limitations to our review may relate to our timeframe of inclusion of studies only from 2000 onwards. Models developed prior to this time may have undergone more thorough testing or validation and clinical impact assessment. However, our rationale for focusing on this contemporary time period was to investigate models appropriate to modern management; with significant changes having taken place in patient management and diagnostic practice since that time.[@R43]

We recognise that exciting developments are also underway to propose genomical or biomarker-based prognostic indicators.[@R52] Many of these are currently reported as single parameter studies, rather than being incorporated into existing models. As such these would not meet the eligibility criteria for this review. As others have suggested, any incremental value of these models should be assessed against 'a gold-standard multivariable clinical prognostic model'.[@R53]

Conclusion {#s5}
==========

Very few long-term prognostic models exist to inform the predominant decision dilemma of whether to undergo treatment or not after first diagnosis of non-metastatic prostate cancer. Current models are limited by inadequate external validation and fall short of many of the expectations of an unbiased, high-quality prognostic model.[@R13] The most robust available tools are the Cambridge Prognostic Groups and the UCSF CAPRA score. However, both have significant shortcomings and are limited in their applicability at diagnosis by failing to include treatment effect, and disregarding non-cancer mortality. Work should focus on developing prognostic models built on long-term survival outcomes which maximally utilise available clinico-pathological information and contextualise PCa within a patients context of competing risks. High quality models including treatment effect are overdue, and crucial if both undertreatment and overtreatment of prostate cancer is to be minimised.
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